Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression

PK. Kopparapu, S. Bhoi, L. Mansouri, LS. Arabanian, K. Plevova, S. Pospisilova, AM. Wasik, GA. Croci, B. Sander, M. Paulli, R. Rosenquist, M. Kanduri,

. 2016 ; 11 (5) : 335-43. [pub] 20160406

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024084

Downregulation of miR26A1 has been reported in various B-cell malignancies; however, the mechanism behind its deregulation remains largely unknown. We investigated miR26A1 methylation and expression levels in a well-characterized series of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). From 450K methylation arrays, we first observed miR26A1 (cg26054057) as uniformly hypermethylated in MCL (n = 24) (all >75%), while CLL (n = 18) showed differential methylation between prognostic subgroups. Extended analysis using pyrosequencing confirmed our findings and real-time quantitative PCR verified low miR26A1 expression in both CLL (n = 70) and MCL (n = 38) compared to normal B-cells. Notably, the level of miR26A1 methylation predicted outcome in CLL, with higher levels seen in poor-prognostic, IGHV-unmutated CLL. Since EZH2 was recently reported as a target for miR26A1, we analyzed the expression levels of both miR26A1 and EZH2 in primary CLL samples and observed an inverse correlation. By overexpression of miR26A1 in CLL and MCL cell lines, reduced EZH2 protein levels were observed using both Western blot and flow cytometry. In contrast, methyl-inhibitor treatment led to upregulated miR26A1 expression with a parallel decrease of EZH2 expression. Finally, increased levels of apoptosis were observed in miR26A1-overexpressing cell lines, further underscoring the functional relevance of miR26A1. In summary, we propose that epigenetic silencing of miR26A1 is required for the maintenance of increased levels of EZH2, which in turn translate into a worse outcome, as shown in CLL, highlighting miR26A1 as a tumor suppressor miRNA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024084
003      
CZ-PrNML
005      
20170830122931.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1080/15592294.2016.1164375 $2 doi
035    __
$a (PubMed)27052808
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kopparapu, Pradeep Kumar $u a Department of Clinical Chemistry and Transfusion Medicine , Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University , Sweden.
245    10
$a Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression / $c PK. Kopparapu, S. Bhoi, L. Mansouri, LS. Arabanian, K. Plevova, S. Pospisilova, AM. Wasik, GA. Croci, B. Sander, M. Paulli, R. Rosenquist, M. Kanduri,
520    9_
$a Downregulation of miR26A1 has been reported in various B-cell malignancies; however, the mechanism behind its deregulation remains largely unknown. We investigated miR26A1 methylation and expression levels in a well-characterized series of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). From 450K methylation arrays, we first observed miR26A1 (cg26054057) as uniformly hypermethylated in MCL (n = 24) (all >75%), while CLL (n = 18) showed differential methylation between prognostic subgroups. Extended analysis using pyrosequencing confirmed our findings and real-time quantitative PCR verified low miR26A1 expression in both CLL (n = 70) and MCL (n = 38) compared to normal B-cells. Notably, the level of miR26A1 methylation predicted outcome in CLL, with higher levels seen in poor-prognostic, IGHV-unmutated CLL. Since EZH2 was recently reported as a target for miR26A1, we analyzed the expression levels of both miR26A1 and EZH2 in primary CLL samples and observed an inverse correlation. By overexpression of miR26A1 in CLL and MCL cell lines, reduced EZH2 protein levels were observed using both Western blot and flow cytometry. In contrast, methyl-inhibitor treatment led to upregulated miR26A1 expression with a parallel decrease of EZH2 expression. Finally, increased levels of apoptosis were observed in miR26A1-overexpressing cell lines, further underscoring the functional relevance of miR26A1. In summary, we propose that epigenetic silencing of miR26A1 is required for the maintenance of increased levels of EZH2, which in turn translate into a worse outcome, as shown in CLL, highlighting miR26A1 as a tumor suppressor miRNA.
650    _2
$a apoptóza $x genetika $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a metylace DNA $x genetika $7 D019175
650    _2
$a EZH2 protein $x biosyntéza $x genetika $7 D000071221
650    _2
$a epigeneze genetická $7 D044127
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x genetika $x patologie $7 D015451
650    _2
$a lymfom z plášťových buněk $x genetika $x patologie $7 D020522
650    _2
$a mikro RNA $x biosyntéza $x genetika $7 D035683
650    _2
$a promotorové oblasti (genetika) $7 D011401
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bhoi, Sujata $u b Department of Immunology , Genetics and Pathology, Science for Life Laboratory, Uppsala University , Uppsala , Sweden.
700    1_
$a Mansouri, Larry $u b Department of Immunology , Genetics and Pathology, Science for Life Laboratory, Uppsala University , Uppsala , Sweden.
700    1_
$a Arabanian, Laleh S $u a Department of Clinical Chemistry and Transfusion Medicine , Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University , Sweden. $7 gn_A_00007917
700    1_
$a Plevova, Karla $u c Central European Institute of Technology, Masaryk University and University Hospital Brno , Czech Republic.
700    1_
$a Pospisilova, Sarka $u c Central European Institute of Technology, Masaryk University and University Hospital Brno , Czech Republic.
700    1_
$a Wasik, Agata M $u d Department of Laboratory Medicine , Division of Pathology, Karolinska University Hospital , Sweden.
700    1_
$a Croci, Giorgio Alberto $u e Department of Molecular Medicine , University of Pavia , Italy.
700    1_
$a Sander, Birgitta $u d Department of Laboratory Medicine , Division of Pathology, Karolinska University Hospital , Sweden.
700    1_
$a Paulli, Marco $u e Department of Molecular Medicine , University of Pavia , Italy.
700    1_
$a Rosenquist, Richard $u b Department of Immunology , Genetics and Pathology, Science for Life Laboratory, Uppsala University , Uppsala , Sweden.
700    1_
$a Kanduri, Meena $u a Department of Clinical Chemistry and Transfusion Medicine , Institute of Biomedicine, Sahlgrenska Academy, Gothenburg University , Sweden.
773    0_
$w MED00180218 $t Epigenetics $x 1559-2308 $g Roč. 11, č. 5 (2016), s. 335-43
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27052808 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170830123520 $b ABA008
999    __
$a ok $b bmc $g 1239765 $s 984997
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 5 $d 335-43 $e 20160406 $i 1559-2308 $m Epigenetics. $n Epigenetics $x MED00180218
LZP    __
$a Pubmed-20170720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace